MODUPE APASSA: Open Payments
NPI 1427069418 · LAUREL, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$697 in 22 payments from 8 companies in 2025. Trend: 2023 $244 · 2024 $481 · 2025 $697
Food & beverage: $697
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $347 |
| Janssen Pharmaceuticals, Inc | 1 | $124 |
| Otsuka America Pharmaceutical, Inc. | 1 | $98 |
| ABBVIE INC. | 2 | $47 |
| Alkermes, Inc. | 2 | $32 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| TMS NeuroHealth Centers Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
Products named: CAPLYTA, INVEGA SUSTENNA, ABILIFY MAINTENA, VRAYLAR, ARISTADA, COBENFY, TMS NeuroHealth Centers Inc., Qelbree.
Industry payments across MD — which companies pay providers there.
